The table below summarizes the annually decreasing review-time goals for original New Drug Applications (NDAs) and BLAs under PDUFA II. Over the five-year period, the goal of reviewing 90 percent of priority applications in six months remains constant. For standard applications, the review-time goals drop over the five-year period. For applications filed in FY 98, the goal was to review 90 percent in 12 months; for FY 02 applications, the goal is to review 90 percent in 10 months. For standard applications filed in FY 2000, the goal was to review 90 percent in 12 months and 50 percent in 10 months.
Goals |
On-Time Performance by Submission Year |
|||||
---|---|---|---|---|---|---|
FY 98 |
FY 99 |
FY 00 |
FY 01 |
FY 02 |
||
Priority |
6 months |
90% on time |
90% |
90% |
90% |
90% |
Standard |
12 months 10 months |
90% |
90% 30% |
90% 50% |
90% 70% |
90% |
The following table shows the number of original NDAs and BLAs filed in each of the last five years. The count of FY 00 submissions assumes that all submissions received in the last two months of FY 00 are filed. When FDA files a submission, it is deemed "complete" by PDUFA definition. FDA makes a filing decision within 60 days of an original application's receipt. All calculations of PDUFA review times are made, however, from the original receipt date of the filed application.
Original submissions filed (Priority/Standard): |
|||||
---|---|---|---|---|---|
FY 96 |
FY 97 |
FY 98 |
FY 99 |
FY 004 |
|
|
106 |
117 (25/92) |
109 (30/79) |
121 (30/91) |
121 (27/94) |
|
9 |
16 (3/13) |
12 (8/4) |
6 (1/5) |
13 (4/9) |
|
115 |
133 (28/105) |
121 (38/83) |
127 (31/96) |
134 (31/103) |
NMEs5 |
42 (19/23) |
41 (16/25) |
35 (17/18) |
FY 99 Submissions:
For FY 99 applications, FDA met the 6-month review goal for priority submissions
and the 12-month goal6 for standard submissions in
every case. Two standard applications submitted late in FY 99 are still pending
but have not exceeded the 12-month goal . Sixty-eight percent of all standard
applications and 60 percent of the NMEs and BLAs were reviewed and acted upon
within 10 months, exceeding the 30 percent review goal in both cases.
FY 99 Submissions |
Reviewed and acted upon |
Number on time |
Percent on time |
||
---|---|---|---|---|---|
Priority |
6 month goal |
All Applications |
31 |
31 |
100 |
NMEs & BLAs |
17 |
17 |
100 |
||
Standard |
12 month goal |
All Applications |
94* |
94 |
100* |
NMEs & BLAs |
30 |
30 |
100 |
||
10 month goal |
All Applications |
94 |
64 |
68 |
|
NMEs & BLAs |
30 |
18 |
60 |
FY 00 Submissions:
While it is too early to report meaningful review performance statistics for standard applications submitted in FY 00, all priority applications that have been reviewed have met the 6 month review goal.
FY 00 Submissions |
Reviewed and acted upon |
Number on time |
Percent on time |
||
---|---|---|---|---|---|
Priority |
6 month goal |
All Applications |
18 |
18 |
100 |
NMEs & BLAs |
9 |
9 |
100 |
||
Standard |
12 month goal |
All Applications |
Too early to report meaningful review performance statistics. Sixteen standard applications have been reviewed and acted upon, all within 10 months. |
||
NMEs & BLAs |
|||||
10 month goal |
All Applications |
||||
NMEs & BLAs |
FDA Home Page | Search | A-Z
Index | Site Map | Contact FDA
FDA/Office of Planning
Web page created by cm 2001-MAR-01.